Clostridium Butyricum miyairi bacteriocin treatment for Clostridioides difficile infections with clinical isolates: Insights from in vitro, ex vivo, and mouse model studies
CBMB-B could be effective in the treatment of CDIs where infections were caused by C. difficile isolates with relative low MICs.
Authors
- I‐Hsiu Huang (ORCID: https://orcid.org/0000-0001-9667-0612)
- Pei-Jane Tsai (ORCID: https://orcid.org/0000-0002-3370-9839)
- Yuan‐Pin Hung (ORCID: https://orcid.org/0000-0003-1006-705X)
- Hung‐Tsung Wu (ORCID: https://orcid.org/0000-0002-0611-8427)
- Wen‐Chien Ko (ORCID: https://orcid.org/0000-0001-7497-149X)
- Hye Jung Chang (ORCID: https://orcid.org/0000-0002-1067-4717)
- Hsiao-Chieh Liu
- Ching‐Chi Lee (ORCID: https://orcid.org/0000-0002-4949-2742)
- Yi-Chen Tu
Institutions
- National University of Tainan (TW)
- Chest Hospital, Ministry of Health and Welfare (TW)
- National Cheng Kung University Hospital (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-03-26
- DOI
- https://doi.org/10.1016/j.jgar.2025.03.007
- Citations
- 1
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 1.40